# Skeletal Fluorosis: A Case Report of Rare Diagnosis of Computer-cleaner Toxicosis

## TL;DR

A 46-year-old woman developed skeletal fluorosis from regularly inhaling a computer cleaner containing difluoroethane, highlighting the need for awareness of this rare condition.

## Contribution

This case report highlights skeletal fluorosis as a rare but serious consequence of computer cleaner inhalation, emphasizing the importance of clinical awareness.

## Key findings

- A patient with chronic inhalation of difluoroethane developed skeletal fluorosis with symptoms including myalgias and joint swelling.
- Radiographic findings showed diffuse periosteal reactions consistent with fluorosis.
- Discontinuation of inhalant use is recommended to prevent prolonged adverse effects.

## Abstract

Skeletal fluorosis is a complication of excess fluoride, which may be associated with chronic inhalation or “huffing” of compressed air cleaners for keyboards and electronics. The rare presentation of this condition can lead to a missed diagnosis and lack of appropriate intervention. Clinicians should be aware of the potential development of fluorosis in patients reporting a history of inhalant abuse.

We present a case of skeletal fluorosis in a 46-year-old female patient with a four-month history of daily inhalant use of computer cleaner containing difluoroethane (DFE). She presented to the emergency department after developing myalgias for approximately four months. The pain was alleviated by rest, heat therapy, and pain medication. She was noted to have diffuse bilateral swelling to upper and lower extremities, as well as interphalangeal joint swelling and non-mobile lesions to bilateral hands and left forearm on physical exam. Radiography revealed diffuse periosteal reaction throughout the hand and forearm suggestive of fluorosis. She was counseled to cease inhalant use.

Skeletal fluorosis is a rare and painful condition that can have prolonged adverse effects and a lasting impact on quality of life. Patients who report regular inhalant use should be counseled on the potential toxicities of these products and encouraged to discontinue use of DFE. Those presenting with diffuse skeletal findings and reported DFE use should be evaluated for skeletal fluorosis.